[1] Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer[J]. Semin Oncol, 2001, 28(2 Suppl 4):S27-29. DOI:10.1016/S0093-7754(01)90075-2.
[2] Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J]. Cancer, 2011, 117(23):5423-5431. DOI:10.1002/cncr.26206.
[3]

Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual[M]. 7th ed. New York:Springer, 2010.
[4] Zhao L, Sheldon K, Chen M, et al. The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer[J]. Lung Cancer, 2008, 59(2):232-239. DOI:10.1016/j.lungcan.2007.08.010.
[5] Eckert F, Müller AC, SCLC extensive disease-treatment guidance by extent or/and biology of response?[J]. Radiat Oncol, 2008, 3:33. DOI:10.1186/1748-717X-3-33.
[6] Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962):36-42. DOI:10.1016/S0140-6736(14)61085-0.
[7] 张文珏, 周宗玫, 陈东福, 等.广泛期SCLC化疗后IMRT的疗效分析[J].中华放射肿瘤学杂志, 2016, 25(1):14-17. DOI:10.3760/cma.j.issn.1004-4221.2016.01.004.
Zhang WJ, Zhou ZM, Chen DF, et al. Clinical outcomes of extensive stage small cell lung cancer patients treated with intensive modified radiotherapy[J]. Chin J Radiat Oncol, 2016, 25(1):14-17.  doi: 10.3760/cma.j.issn.1004-4221.2016.01.004
[8] Shi A, Zhu G, Wu H, et al. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Radiat Oncol, 2010, 5:35. DOI:10.1186/1748-717X-5-35.
[9] Wen J, Liu H, Wang Q, et al. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy[J]. Eur J Cancer, 2014, 50(10):1706-1716. DOI:10.1016/j.ejca.2014.03.008.
[10] Claude L, Pérol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer:clinical and dosimetric factors analysis[J]. Radiother Oncol, 2004, 71(2):175-181. DOI:10.1016/j.radonc.2004.02.005.
[11] Mao J, Kocak Z, Zhou S, et al. The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response[J]. Int J Radiat Oncol Biol Phys, 2007, 67(5):1360-1369. DOI:10.1016/j.ijrobp.2006.11.003.
[12] Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer(NSCLC)[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2):323-329.  doi: 10.1016/S0360-3016(99)00183-2
[13] Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis(TRP) in patients with non-small-cell lung cancer(NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy(3D-CRT)[J]. Int J Radiat Oncol Biol Phys, 2006, 66(5):1399-1407. DOI:10.1016/j.ijrobp.2006.07.1337.
[14] Yao B, Wang YD, Liu QZ. Radiation pneumonitis in non-small-cell lung cancer patients treated with helical tomotherapy[J]. Niger J Clin Pract, 2016, 19(1):25-29. DOI:10.4103/1119-3077.173709.
[15] Kim Y, Hong SE, Kong M, et al. Predictive factors for radiation pneumonitis in lung cancer treated with helical tomotherapy[J]. Cancer Res Treat, 2013, 45(4):295-302. DOI:10.4143/crt.2013.45.4.295.
[16] Song CH, Pyo H, Moon SH, et al. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):651-658. DOI:10.1016/j.ijrobp.2009.08.068.